Detail akcie Biocryst Pharm online

Business Summary: BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.
Financial Summary: BRIEF: For the six months ended 30 June 2026, BioCryst Pharmaceuticals Inc revenues increased 21% to $374.7M. Net loss totaled $643.4M vs. income of $5.1M. Revenues reflect ORLADEYO segment increase from $163.4M to $374.7M. Net loss reflects ORLADEYO segment loss totaling $603.1M vs. income of $29.8M. Basic Earnings per Share excluding Extraordinary Items decreased from $0.02442 to -$2.67146.